pirfenidone (esbriet) Report issue

Small molecule Orphan Drug FDA Approved FDA Fast Track FDA Priority Review FDA

Active Ingredient History

  • Now
Pirfenidone is a synthetic antifibrotic agent indicated for the treatment of idiopathic pulmonary fibrosis as Esbriet. Pirfenidone inhibits fibroblast, epidermal, platelet-derived, and transforming beta-1 growth factors. It also inhibits DNA synthesis and the production of mRNA for collagen types I and III, resulting in a reduction in radiation-induced fibrosis. Pirfenidone has demonstrated activity in multiple fibrotic conditions however the exact mechanism of action of pirfenidone in the treatment of IPF has not been established.   NCATS

  • SMILES: CC1=CN(C(=O)C=C1)C2=CC=CC=C2
  • Mol. Mass: 185.2218
  • ALogP: 2.15
  • ChEMBL Molecule:
More Chemistry
  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Oral
  • Pro Drug: No

Drug Pricing (per unit)


$8.5258 - $25.5775

United States

$26.3360 - $106.3590
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

5-methyl-1-phenyl-2-(1h)-pyridone | amr-69 | deskar | esbriet | glaspia | pirfenidone


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue